Zai Lab announces China NMPA acceptance of repotrectinib sNDA

Zai Lab (ZLAB) announced that China’s National Medical Products Administration has accepted the supplemental new drug application for repotrectinib for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase gene fusion. The application is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to result in severe morbidity, and who have either progressed following prior therapies or have no satisfactory alternative treatment options.